Abstract
Los glioblastomas multiformes son tumores agresivos del sistema nervioso central cuya morbilidad y mortalidad permanecen muy elevadas a pesar del tratamiento. Se han reportado numerosas alteraciones moleculares asociadas, pero solo unas pocas se asocian con la supervivencia. En el artículo se revisan las alteraciones moleculares y las perspectivas de diagnóstico y tratamiento en relación con el tema. Se presentan siete pacientes del Instituto Nacional de Cancerología- INC que superaron los dos años de sobrevida, reportando las características clínicas y de tratamiento que fueron importantes para la sobrevida. Se resalta también la importancia de estandarizar los marcadores biomoleculares junto a los hallazgos histológicos para mejorar el conocimiento de estos tumores.
References
HUTTNER A. Overview of primary brain tumors pathologic classification, epidemiology, molecular biology, and prognostic markers. Hematol Oncol Clin N Am. 2012; 26:715–732.
HOLDHOFF M, YOVINO SG, BOADU O, GROSSMAN SA. Blood-based biomarkers for malignant gliomas. J Neurooncol. 2013; 113:345–352.
BLEEKER FE, MOLENAAR RJ, LEENSTRA S. Recent advances in the molecular understanding of glioblastoma. J Neurooncol. 2012; 108:11–27.
JANSEN M, YIP S, LOUIS DN. Molecular pathology in adult gliomas: Diagnostic, prognostic, and predictive markers. Lancet Neurol. 2010; 9: 717–26
SUVA ML, LOUIS DN. Next-generation molecular genetics of brain tumours. Curr Opin Neurol. 2013; 26:681–687.
HOLDHOFF M, CHAMBERLAIN MC. Controversies in the treatment of elderly patients with newly diagnosed glioblastoma. J Natl Compr Canc Netw. 2013; 11:1165-1173.
ANTON K, BAEHRING JM, MAYER T. Glioblastoma Multiforme Overview of Current Treatment and Future Perspectives. Hematol Oncol Clin N Am. 2012; 26:825–853.
TABATABAIA G, STUPP R, WICK W, WELLERA M. Malignant astrocytoma in elderly patients: Where do we stand? Curr Opin Neurol. 2013; 26:693–700
POPOVA S, BERGQVIST M, DIMBERG A, EDQVIST P, EKMAN S, HESSELAGER G, ET AL. Subtyping of gliomas of various WHO grades by the application of immunohistochemistry. Histopathology. 2014; 64:365–379.
YANA K, YANGA K, RICH J. The evolving landscape of glioblastoma stem cells. Curr Opin Neurol. 2013; 26:701–707
THOMAS R, XU LX, LOBER R, GORDON LI G, NAGPAL S. The incidence and significance of multiple lesions in glioblastoma. J Neurooncol (2013) 112:91–97.
HUNDSBERGER T, BRUGGE D, PUTORA P, WEDER P, WEBER J, PLASSWILM L. Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas. J Neurooncol. 2013; 112:133–139.
HERMANSEN S, DAHLROT R, NIELSEN B, HANSEN S, KRISTENSEN B. MiR-21 expression in the tumor cell compartment holds unfavorable prognostic value in gliomas. J Neurooncol. 2013; 111:71–8.
HEGIA M, RAJAKANNUA P, WELLER M. Epidermal growth factor receptor: A re-emerging target in glioblastoma. Curr Opin Neurol. 2012; 25:774–779.
BLAKE L, MARAVILLA K. Computed Tomografhy. In: Berger M, Wilson CB, eds. The gliomas. Philadelphia: WB Saunders, 1999. p. 242-74.
SANAI N. Emerging operative strategies in neurosurgical oncology. Curr Opin Neurol. 2012; 25:756–766.
DUTZMANN S, GESSLER F, BINK A, QUICK J, FRANZ K, SEIFERT V ET AL. Risk of ischemia in glioma surgery: comparison of first and repeat Procedures. J Neurooncol. 2012; 107:599–607.
MALKOUN N, CHARGARI C, FOREST F, FOTSO M, CARTIER L, AUBERDIAC P. ET AL. Prolonged temozolomide for treatment of glioblastoma:preliminary clinical results and prognostic value of p53 overexpression. J Neurooncol. 2012; 106:127–133.
VAN MEIR E, HADJIPANAYIS C, NORDEN A, SHU H, WEN P, OLSON J. Exciting New Advances in Neuro- Oncology: The Avenue to a Cure for Malignant Glioma. CA Cancer J Clin. 2010; 60:166–193,
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.